查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584121

癌症生物標記市場，按生物標記類型、癌症類型、應用、國家和地區 - 2024-2032年產業分析、市場規模、市場佔有率和預測

Cancer Biomarkers Market, By Biomarker Type, By Cancer Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年癌症生物標記市場規模為289.2841億美元，2024年至2032年年複合成長率為12.90%。

癌症生物標記市場-市場動態

對個人化醫療的需求不斷成長推動了癌症生物標記市場的成長

對個人化醫療的需求不斷成長，大幅推動了癌症生物標記市場的成長，因為它允許更有針對性和更有效的癌症治療。美國國立衛生研究院（NIH）和世界衛生組織（WHO）等組織強調生物標記在推進精準腫瘤學方面的重要性，特別是考慮到2020年至2040年間全球癌症病例預計將增加 47%。強調BRCA1 和BRCA2 等生物標記在評估乳癌和卵巢癌風險方面發揮關鍵作用。此外，生物標記驅動的療法擴大被納入臨床指南，從美國 FDA 在過去十年中批准了多種基於生物標記的治療方法即可看出。這些進步推動癌症診斷和治療途徑的研究和創新。

癌症生物標記市場 - 關鍵見解

根據研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 12.90%左右的年複合成長率成長

根據生物標記類型細分，預計遺傳生物標記將在2023年顯示出最大的市場佔有率

根據癌症類型細分，乳癌是2023年的主要癌症類型

依地區分類，北美是2023年的主要收入來源

癌症生物標記市場-細分分析：

全球癌症生物標記市場根據生物標記類型、癌症類型、應用和區域進行細分。

根據生物標記類型，市場分為四類：遺傳生物標記、蛋白質生物標記、表觀遺傳生物標記和代謝生物標記。遺傳生物標記因其在癌症診斷和個人化治療中的關鍵作用而具有最高優先事項。隨後出現蛋白質生物標記物，這對於監測疾病進展非常重要。表觀遺傳和代謝生物標記越來越重要，但在臨床應用的排名略低。

根據癌症類型，市場分為兩類：乳癌、肺癌、大腸癌和攝護腺癌。由於乳癌的高發生率和廣泛的研究，乳癌生物標記成為重中之重。鑑於其死亡率和生物標記的進步，肺癌緊隨其後。大腸直腸癌排名第三，診斷焦點不斷增加，而前列腺癌生物標記在市場上的優先順序略低。

癌症生物標記市場 - 地理洞察

在先進的醫療基礎設施和精準醫學的重大研發投資的推動下，北美在癌症生物標記市場佔據主導地位。美國在該地區處於領先地位，美國國家癌症研究所（NCI）資助了多項生物標記研究計畫，預計2021年將新增約190萬癌症病例。歐洲緊隨其後，歐盟的Horizon 2020計畫等措施為生物標記驅動的癌症研究分配了大量資金，特別是在英國和德國。在亞太地區，醫療保健的快速進步和癌症盛行率的上升，特別是在中國和印度，推動市場成長。中國國家癌症中心報告每年新增癌症病例超過 450萬例，促使政府投資生物標記開發。拉丁美洲、中東和非洲是新興地區，人們的認知不斷提高，政府採取的措施（例如巴西國家癌症研究所）在早期診斷和生物標記採用方面的努力也不斷提高。這些地理動態反映了全球癌症生物標記市場的不同焦點和發展。

癌症生物標記市場-競爭格局：

癌症生物標記市場的競爭格局高度活躍，北美由於主要參與者的存在和頻繁的創新而處於領先地位。 Thermo Fisher Scientific 和 Roche Diagnostics 等公司在該地區佔據主導地位，Roche 最近推出了 Elecsys（R）PD-L1 生物標記測試，增強了其腫瘤診斷產品組合。在歐洲，Qiagen 和 Bio-Rad Laboratories 是透過策略合作推動市場的主要參與者。例如，2022年，Qiagen 與 Neuron23 合作開發神經退化性疾病的伴隨診斷，將其重點擴大到基於生物標記的治療。亞太地區的競爭日益激烈，中國BGI Genomics等公司紛紛建立國際合作關係以利用生物標記研究。2021年，Quest Diagnostics 收購了總部位於印度的Strand Life Sciences，以增強其腫瘤檢測能力。拉丁美洲、中東和非洲仍在發展中，但不斷成長的合作夥伴關係和投資表明人們對基於生物標記的癌症解決方案的興趣日益濃厚，公司致力於擴大在這些地區的業務。

最新進展：

2024年 8月，Illumina 的TruSight Oncology Excellent 測試獲得 FDA 批准，成為第一個針對癌症的綜合基因組分析 IVD 試劑盒。它分析了 500 多個基因，有助於為患有特定實體瘤和基因融合的患者進行標靶治療配對。

2024年 10月，AstraZeneca計劃推出生物標記驅動的療法作為傳統化療的替代方案。該公司目的是透過致力於精準醫療、根據遺傳標記和腫瘤特徵針對特定癌症類型提供客製化治療來提高患者治療效果。

目錄

第1章 癌症生物標記市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 依生物標記類型分類的癌症生物標記市場摘錄
    • 依癌症類型分類的癌症生物標記市場摘錄
    • 依應用分類的癌症生物標記市場摘錄
    • 依國家分類的癌症生物標記市場摘錄
    • 依地區分類的癌症生物標記市場摘錄
  • 競爭洞察

第3章 癌症生物標記主要市場趨勢

  • 癌症生物標記市場促進因素
    • 市場促進因素的影響分析
  • 癌症生物標記市場限制
    • 市場限制影響分析
  • 癌症生物標記市場機會
  • 癌症生物標記市場未來趨勢

第4章 癌症生物標記產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 癌症生物標記市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 癌症生物標記市場格局

  • 2023年癌症生物標記市場佔有率分析
  • 依主要製造商分類的細分資料
    • 既有參與者分析
    • 新興參與者分析

第7章 癌症生物標記市場 - 依生物標記類型

  • 概述
    • 依生物標記類型分類的細分市場佔有率分析
    • 基因生物標記
    • 蛋白質生物標記
    • 表觀遺傳生物標記
    • 代謝生物標記

第8章 癌症生物標記市場 - 依癌症類型

  • 概述
    • 依癌症類型分類的細分市場佔有率分析
    • 乳癌
    • 肺癌
    • 大腸直腸癌
    • 攝護腺癌

第9章 癌症生物標記市場 - 依應用

  • 概述
    • 依應用分類的細分市場佔有率分析
    • 診斷
    • 預後
    • 藥物發現與開發
    • 個人化醫療

第10章 癌症生物標記市場 - 依地理位置

  • 介紹
    • 依地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美癌症生物標記主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依生物標記類型）
    • 北美市場規模和預測（依癌症類型）
    • 北美市場規模和預測（依應用）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲癌症生物標記主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依生物標記類型）
    • 歐洲市場規模和預測（依癌症類型）
    • 歐洲市場規模和預測（依應用）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區癌症生物標記主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模和預測（依生物標記類型）
    • 亞太地區市場規模和預測（依癌症類型）
    • 亞太地區市場規模與預測（依應用）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲癌症生物標記主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模和預測（依生物標記類型）
    • 拉丁美洲市場規模與預測（依癌症類型）
    • 拉丁美洲市場規模與預測（依應用）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲癌症生物標記主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依生物標記類型）
    • 中東和非洲市場規模及預測（依癌症類型）
    • 中東和非洲市場規模及預測（依應用）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA其他地區

第11章 主要供應商分析 - 癌症生物標記產業

  • 競爭儀表板
  • 公司簡介
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • Exact Sciences Corporation
    • Foundation Medicine, Inc.（Roche）
    • GE Healthcare（General Electric Company）
    • Guardant Health, Inc.
    • Hologic, Inc.
    • Illumina, Inc.
    • Myriad Genetics, Inc.
    • NeoGenomics, Inc.
    • PerkinElmer, Inc.
    • Qiagen NV
    • Roche Diagnostics（F. Hoffmann-La Roche AG）
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Others

第12章 360 度分析師視角

第13章 附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4104

REPORT HIGHLIGHT

Cancer Biomarkers Market size was valued at USD 28,928.41 million in 2023, expanding at a CAGR of 12.90% from 2024 to 2032.

The Cancer Biomarkers Market refers to identifying and utilizing biological molecules that indicate the presence of cancer in the body, aiding in diagnosis, prognosis, and therapy selection. Increasing demand for personalized medicine, advances in omics technologies, and growing investments in cancer research are boosting market growth. The rising prevalence of cancer globally, with an estimated 19.3 million new cases reported in 2020, underscores the need for efficient diagnostic tools. However, the high costs of biomarker validation and stringent regulatory requirements pose challenges to market expansion. Emerging opportunities lie in developing non-invasive liquid biopsy techniques, which are gaining attention for their potential to improve early cancer detection and monitoring.

Cancer Biomarkers Market- Market Dynamics

Rising Demand for Personalized Medicine Fuels Growth in the Cancer Biomarkers Market

Rising demand for personalized medicine is significantly driving the growth of the Cancer Biomarkers Market as it allows for more targeted and effective cancer treatments. Organizations like the National Institutes of Health (NIH) and the World Health Organization (WHO) emphasize the importance of biomarkers in advancing precision oncology, especially with global cancer cases expected to rise by 47% between 2020 and 2040. For instance, the American Cancer Society has highlighted how biomarkers such as BRCA1 and BRCA2 are pivotal in assessing breast and ovarian cancer risks. Additionally, biomarker-driven therapies are increasingly being incorporated into clinical guidelines, as seen in the U.S. FDA's approval of multiple biomarker-based treatments over the past decade. These advancements are propelling research and innovation in cancer diagnostics and treatment pathways.

Cancer Biomarkers Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.90% over the forecast period (2024-2032)

Based on Biomarker Type segmentation, Genetic biomarkers were predicted to show maximum market share in the year 2023

Based on Cancer Type segmentation, Breast cancer was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cancer Biomarkers Market- Segmentation Analysis:

The Global Cancer Biomarkers Market is segmented on the basis of Biomarker Type, Cancer Type, Application, and Region.

The market is divided into four categories based on Biomarker Type: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, and Metabolic Biomarkers. Genetic biomarkers hold the highest priority due to their critical role in cancer diagnosis and personalized therapies. Protein biomarkers follow, essential for monitoring disease progression. Epigenetic and metabolic biomarkers are gaining importance but rank slightly lower in clinical applications.

The market is divided into two categories based on Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, and Prostate Cancer. Breast cancer biomarkers take top priority due to high incidence and extensive research. Lung cancer follows closely, given its mortality rate and biomarker advancements. Colorectal cancer ranks third, with increasing diagnostic focus, while prostate cancer biomarkers hold slightly lower priority in the market.

Cancer Biomarkers Market- Geographical Insights

North America dominates the Cancer Biomarkers Market, driven by advanced healthcare infrastructure and significant R&D investments in precision medicine. The U.S. leads the region, with the National Cancer Institute (NCI) funding multiple biomarker research programs, contributing to around 1.9 million new cancer cases in 2021. Europe follows closely, where initiatives like the European Union's Horizon 2020 program have allocated substantial funding for biomarker-driven cancer research, particularly in the UK and Germany. In the Asia-Pacific region, rapid healthcare advancements and increasing cancer prevalence, notably in China and India, are fueling market growth. China's National Cancer Center reported over 4.5 million new cancer cases annually, prompting the government to invest in biomarker development. Latin America and the Middle East & Africa are emerging regions, with increasing awareness and government initiatives like Brazil's National Cancer Institute efforts in early diagnosis and biomarker adoption. These geographical dynamics reflect the varied focus and development of the cancer biomarkers market globally.

Cancer Biomarkers Market- Competitive Landscape:

The Cancer Biomarkers Market's competitive landscape is highly dynamic, with North America leading due to the presence of major players and frequent innovations. Companies like Thermo Fisher Scientific and Roche Diagnostics dominate the region, with Roche recently launching its Elecsys(R) PD-L1 biomarker test, enhancing its oncology diagnostics portfolio. In Europe, Qiagen and Bio-Rad Laboratories are key players driving the market with strategic collaborations. For instance, in 2022, Qiagen collaborated with Neuron23 to develop companion diagnostics for neurodegenerative diseases, expanding its focus on biomarker-based therapies. The Asia-Pacific region is witnessing rising competition, with companies like China's BGI Genomics entering international partnerships to leverage biomarker research. In 2021, India-based Strand Life Sciences was acquired by Quest Diagnostics to bolster its oncology testing capabilities. Latin America and the Middle East & Africa are still developing, but growing partnerships and investments indicate a rising interest in biomarker-based cancer solutions, with companies focusing on expanding their presence in these regions.

Recent Developments:

In August 2024, Illumina's TruSight Oncology Comprehensive test received FDA approval as the first comprehensive genomic profiling IVD kit for cancer. It profiles over 500 genes, aiding in targeted therapy matching for patients with specific solid tumors and gene fusions.

In October 2024, AstraZeneca plans to launch biomarker-driven therapies as alternatives to traditional chemotherapy. The company aims to enhance patient outcomes by focusing on precision medicine, targeting specific cancer types with tailored treatments based on genetic markers and tumor characteristics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CANCER BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine, Inc. (Roche)
  • GE Healthcare (General Electric Company)
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics, Inc.
  • PerkinElmer, Inc.
  • Qiagen N.V.
  • Roche Diagnostics (F. Hoffmann-La Roche AG)
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Others

GLOBAL CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Genetic Biomarkers
  • Protein Biomarkers
  • Epigenetic Biomarkers
  • Metabolic Biomarkers

GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE- MARKET ANALYSIS, 2019 - 2032

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer

GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Diagnosis
  • Prognosis
  • Drug Discovery and Development
  • Personalized Medicine

GLOBAL CANCER BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cancer Biomarkers Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cancer Biomarkers Market Snippet by Biomarker Type
    • 2.1.2. Cancer Biomarkers Market Snippet by Cancer Type
    • 2.1.3. Cancer Biomarkers Market Snippet by Application
    • 2.1.4. Cancer Biomarkers Market Snippet by Country
    • 2.1.5. Cancer Biomarkers Market Snippet by Region
  • 2.2. Competitive Insights

3. Cancer Biomarkers Key Market Trends

  • 3.1. Cancer Biomarkers Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cancer Biomarkers Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cancer Biomarkers Market Opportunities
  • 3.4. Cancer Biomarkers Market Future Trends

4. Cancer Biomarkers Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cancer Biomarkers Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cancer Biomarkers Market Landscape

  • 6.1. Cancer Biomarkers Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cancer Biomarkers Market - By Biomarker Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Biomarker Type, 2023 & 2032 (%)
    • 7.1.2. Genetic Biomarkers
    • 7.1.3. Protein Biomarkers
    • 7.1.4. Epigenetic Biomarkers
    • 7.1.5. Metabolic Biomarkers

8. Cancer Biomarkers Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2023 & 2032 (%)
    • 8.1.2. Breast Cancer
    • 8.1.3. Lung Cancer
    • 8.1.4. Colorectal Cancer
    • 8.1.5. Prostate Cancer

9. Cancer Biomarkers Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 9.1.2. Diagnosis
    • 9.1.3. Prognosis
    • 9.1.4. Drug Discovery and Development
    • 9.1.5. Personalized Medicine

10. Cancer Biomarkers Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Cancer Biomarkers Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Cancer Biomarkers Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Cancer Biomarkers Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Cancer Biomarkers Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Cancer Biomarkers Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Cancer Biomarkers Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Abbott Laboratories
    • 11.2.2. Agilent Technologies, Inc.
    • 11.2.3. Bio-Rad Laboratories, Inc.
    • 11.2.4. Exact Sciences Corporation
    • 11.2.5. Foundation Medicine, Inc. (Roche)
    • 11.2.6. GE Healthcare (General Electric Company)
    • 11.2.7. Guardant Health, Inc.
    • 11.2.8. Hologic, Inc.
    • 11.2.9. Illumina, Inc.
    • 11.2.10. Myriad Genetics, Inc.
    • 11.2.11. NeoGenomics, Inc.
    • 11.2.12. PerkinElmer, Inc.
    • 11.2.13. Qiagen N.V.
    • 11.2.14. Roche Diagnostics (F. Hoffmann-La Roche AG)
    • 11.2.15. Siemens Healthineers AG
    • 11.2.16. Thermo Fisher Scientific Inc.
    • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us